



## Semaglutide and Tirzepatide for Obesity

### Draft Questions for Deliberation and Voting: November 13<sup>th</sup> Public Meeting

*These questions are intended for the deliberation of the New England CEPAC voting body at the public meeting.*

**Patient Population for all questions:** *Adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, who are actively seeking medical management for weight loss; adults with established diabetes are excluded.*

#### Clinical Evidence

1. Is the currently available evidence adequate to distinguish the net health benefit *between* tirzepatide and injectable semaglutide?

Yes

No

- a. If "Yes", which has a greater net health benefit?

2. Is the currently available evidence adequate to distinguish the net health benefit *between oral* semaglutide and *injectable* semaglutide?

Yes

No

- a. If "Yes", which has a greater net health benefit?

## Benefits Beyond Health and Special Ethical Priorities

To help inform judgments of overall long-term value for money, please indicate your level of agreement with the following statements:

1=Strongly Disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree

3. There is substantial unmet need despite currently available treatments.
4. This condition is of substantial relevance for people from a racial/ethnic group that has not been equitably served by the healthcare system.

To help inform judgments of overall long-term value for money, please indicate your level of agreement with the following statements:

1=Strongly Disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree

5. Injectable semaglutide, compared with lifestyle modification alone, is likely to produce substantial improvement in caregivers' quality of life and/or ability to pursue their own education, work, and family life.
6. Oral semaglutide, compared with lifestyle modification alone, is likely to produce substantial improvement in caregivers' quality of life and/or ability to pursue their own education, work, and family life.
7. Tirzepatide, compared with lifestyle modification alone, is likely to produce substantial improvement in caregivers' quality of life and/or ability to pursue their own education, work, and family life.
8. Oral semaglutide offers a substantial opportunity to improve access to effective treatment by means of its mechanism of action or method of delivery.

## Long-Term Value for Money

9. Given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering benefits beyond health and special ethical priorities, what is the long-term value for money of injectable semaglutide added onto lifestyle modification compared to lifestyle modification alone at current pricing?
  - a. High long-term value for money at current pricing
  - b. Intermediate long-term value for money at current pricing
  - c. Low long-term value for money at current pricing
10. Given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering benefits beyond health and special ethical priorities, what is the long-term value for money of oral semaglutide added onto lifestyle modification compared to lifestyle modification alone at assumed pricing?
  - d. High long-term value for money at assumed pricing

- e. Intermediate long-term value for money at assumed pricing
  - f. Low long-term value for money at assumed pricing
11. Given the available evidence on comparative clinical effectiveness and incremental cost effectiveness, and considering benefits beyond health and special ethical priorities, what is the long-term value for money of tirzepatide added onto lifestyle modification compared to lifestyle modification alone at current pricing?
- g. High long-term value for money at current pricing
  - h. Intermediate long-term value for money at current pricing
  - i. Low long-term value for money at current pricing